Normal-high IGF-1 level improves pregnancy rate after ovarian stimulation in women treated with growth hormone replacement therapy
Objective: Growth hormone (GH) and insulin-like growth factors (IGFs) are not mandatory for reproductive life, but data suggest their synergistic action with follicle-stimulating hormone throughout ovarian folliculogenesis. We aimed to evaluate the association of IGF-1 level on clinical pregnancy ra...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2022-11-01
|
| Series: | Endocrine Connections |
| Subjects: | |
| Online Access: | https://ec.bioscientifica.com/view/journals/ec/11/12/EC-22-0241.xml |
| _version_ | 1797990336952270848 |
|---|---|
| author | Nathalie Ly Sophie Dubreuil Philippe Touraine |
| author_facet | Nathalie Ly Sophie Dubreuil Philippe Touraine |
| author_sort | Nathalie Ly |
| collection | DOAJ |
| description | Objective: Growth hormone (GH) and insulin-like growth factors (IGFs) are not mandatory for reproductive life, but data suggest their synergistic action with follicle-stimulating hormone throughout ovarian folliculogenesis. We aimed to evaluate the association of IGF-1 level on clinical pregnancy rate after ovarian stimulation, with or without intrauterine insemination, in women with GH deficiency (GHD) tre ated with GH replacement therapy (GHRT) at conception.
Design and methods: Data from 19 women with both GHD and hypogonadotropic hypogonadism referred to our reproductive medicine department were retrospectively collected. IGF-1 levels were assessed in a single laboratory, and values were expressed in s.d. from the mean.
Results: Amongst the seven patients receiving GHRT during ovarian stimulation, higher IGF-1 levels were significantly associated with clinical pregnan cy (+0.4 s.d. vs –1.6 s.d., P = 0.03). Amongst the 24 pregnancies obtained by the 19 infertile patients, pregnancy loss was less frequent with the addition of GHRT than without (1 miscarriage out of 8 total pregnancies vs 4 miscarriages out of 16 total pregnancies ).
Conclusions: This is the first study evaluating the association of IGF-1 lev el on clinical pregnancy rate in GH-treated women at conception. When taking care of female infertility due to hypogonadotropic hypogonadism, practitioners should enquire about the associated GHD and IGF-1 levels. To ensure higher clinical pregnancy chances, practitioners should aim for IGF-1 values at conception, ranging from 0 s.d. to +2 s.d., and, if necessary, could discuss initiation or increase GH treatment. Prospective studies should help strengthen our results. |
| first_indexed | 2024-04-11T08:34:58Z |
| format | Article |
| id | doaj.art-dc85d075965449efad5a5c6193821f30 |
| institution | Directory Open Access Journal |
| issn | 2049-3614 |
| language | English |
| last_indexed | 2024-04-11T08:34:58Z |
| publishDate | 2022-11-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Connections |
| spelling | doaj.art-dc85d075965449efad5a5c6193821f302022-12-22T04:34:22ZengBioscientificaEndocrine Connections2049-36142022-11-01111218https://doi.org/10.1530/EC-22-0241Normal-high IGF-1 level improves pregnancy rate after ovarian stimulation in women treated with growth hormone replacement therapyNathalie Ly0Sophie Dubreuil1Philippe Touraine2Department of Endocrinology and Reproductive Medicine, Reference Center for Rare Endocrine Diseases of Growth and Development, Reference Center for Gynecological Rare Diseases, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France; EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, FranceDepartment of Endocrinology and Reproductive Medicine, Reference Center for Rare Endocrine Diseases of Growth and Development, Reference Center for Gynecological Rare Diseases, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France; EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, FranceDepartment of Endocrinology and Reproductive Medicine, Reference Center for Rare Endocrine Diseases of Growth and Development, Reference Center for Gynecological Rare Diseases, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France; EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France; Sorbonne University, Paris, FranceObjective: Growth hormone (GH) and insulin-like growth factors (IGFs) are not mandatory for reproductive life, but data suggest their synergistic action with follicle-stimulating hormone throughout ovarian folliculogenesis. We aimed to evaluate the association of IGF-1 level on clinical pregnancy rate after ovarian stimulation, with or without intrauterine insemination, in women with GH deficiency (GHD) tre ated with GH replacement therapy (GHRT) at conception. Design and methods: Data from 19 women with both GHD and hypogonadotropic hypogonadism referred to our reproductive medicine department were retrospectively collected. IGF-1 levels were assessed in a single laboratory, and values were expressed in s.d. from the mean. Results: Amongst the seven patients receiving GHRT during ovarian stimulation, higher IGF-1 levels were significantly associated with clinical pregnan cy (+0.4 s.d. vs –1.6 s.d., P = 0.03). Amongst the 24 pregnancies obtained by the 19 infertile patients, pregnancy loss was less frequent with the addition of GHRT than without (1 miscarriage out of 8 total pregnancies vs 4 miscarriages out of 16 total pregnancies ). Conclusions: This is the first study evaluating the association of IGF-1 lev el on clinical pregnancy rate in GH-treated women at conception. When taking care of female infertility due to hypogonadotropic hypogonadism, practitioners should enquire about the associated GHD and IGF-1 levels. To ensure higher clinical pregnancy chances, practitioners should aim for IGF-1 values at conception, ranging from 0 s.d. to +2 s.d., and, if necessary, could discuss initiation or increase GH treatment. Prospective studies should help strengthen our results.https://ec.bioscientifica.com/view/journals/ec/11/12/EC-22-0241.xmlgrowth hormonegrowth hormone deficiencyhypopituitarismpregnancyigf-1ovarian stimulationintrauterine inseminationassisted reproductive technology |
| spellingShingle | Nathalie Ly Sophie Dubreuil Philippe Touraine Normal-high IGF-1 level improves pregnancy rate after ovarian stimulation in women treated with growth hormone replacement therapy Endocrine Connections growth hormone growth hormone deficiency hypopituitarism pregnancy igf-1 ovarian stimulation intrauterine insemination assisted reproductive technology |
| title | Normal-high IGF-1 level improves pregnancy rate after ovarian stimulation in women treated with growth hormone replacement therapy |
| title_full | Normal-high IGF-1 level improves pregnancy rate after ovarian stimulation in women treated with growth hormone replacement therapy |
| title_fullStr | Normal-high IGF-1 level improves pregnancy rate after ovarian stimulation in women treated with growth hormone replacement therapy |
| title_full_unstemmed | Normal-high IGF-1 level improves pregnancy rate after ovarian stimulation in women treated with growth hormone replacement therapy |
| title_short | Normal-high IGF-1 level improves pregnancy rate after ovarian stimulation in women treated with growth hormone replacement therapy |
| title_sort | normal high igf 1 level improves pregnancy rate after ovarian stimulation in women treated with growth hormone replacement therapy |
| topic | growth hormone growth hormone deficiency hypopituitarism pregnancy igf-1 ovarian stimulation intrauterine insemination assisted reproductive technology |
| url | https://ec.bioscientifica.com/view/journals/ec/11/12/EC-22-0241.xml |
| work_keys_str_mv | AT nathaliely normalhighigf1levelimprovespregnancyrateafterovarianstimulationinwomentreatedwithgrowthhormonereplacementtherapy AT sophiedubreuil normalhighigf1levelimprovespregnancyrateafterovarianstimulationinwomentreatedwithgrowthhormonereplacementtherapy AT philippetouraine normalhighigf1levelimprovespregnancyrateafterovarianstimulationinwomentreatedwithgrowthhormonereplacementtherapy |